Nuvectis Pharma, Inc.
NVCT· Nasdaq
Released Nov 8, 2023, before the open
10-Q filed Nov 8, 2023, 39 days after period end · 0001558370-23-018124
| Metric | Q3 2023 | Q3 2022 | Q3 2021 |
|---|---|---|---|
| Net Income | -$5.88M | -$5.88M | -$4.67M |
| EPS Diluted | -$0.37 | -$0.42 | -$1.04 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Nuvectis Pharma, Inc. · CIK 1875558 · Engraved from SEC EDGAR
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
ended Sep 30, 2023 · filed Nov 8, 2023 · 39 d after period end
9.8% from the close of Nov 7, 2023 to the close of Nov 10, 2023, the first after the release.